Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder

Abstract

MPH and DEX are cost-effective interventions for childhood ADHD. DEX is more cost-effective than MPH, although if MPH were listed at a lower price on the Pharmaceutical Benefits Scheme it would become more cost-effective. Increased uptake of stimulants for ADHD would require policy change. However, the medication of children and wider availability of stimulants may concern parents and the community.

Cost Effectiveness of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder

“…A further review of these 45 published full-text reports excluded 32 conference submissions, abstracts or review articles and 13 full-text studies were included in the final review (figure 1). [53][54][55][56][57][58][59][60][61][62][63][64][65] To facilitate comparisons across studies, costs were reported in the original currency as well as in 2010 US dollars. Costs in non-US currencies were first converted to US dollars in the same year based on the annual exchange rate in that year.…”

“…behavioural or community care] (6), [55,57,58,[63][64][65] stimulants versus non-stimulants (3) [60][61][62] and stimulants versus stimulants (7). [54][55][56][57][58][59]62] Several studies included more than one category.…”

“…behavioural or community care] (6), [55,57,58,[63][64][65] stimulants versus non-stimulants (3) [60][61][62] and stimulants versus stimulants (7). [54][55][56][57][58][59]62] Several studies included more than one category. [54,55,57,58,[60][61][62] The majority of studies were conducted in the US (4) [54,56,64,65] and UK (5); [53,57,60,62,63] the remaining studies were conducted in Canada (1), [55] Australia (1), [58] the Netherlands (1) [59] and Spain (1).…”

“…[54][55][56][57][58][59]62] Several studies included more than one category. [54,55,57,58,[60][61][62] The majority of studies were conducted in the US (4) [54,56,64,65] and UK (5); [53,57,60,62,63] the remaining studies were conducted in Canada (1), [55] Australia (1), [58] the Netherlands (1) [59] and Spain (1). [61] Six studies conducted cost-utility analyses (CUAs) using quality-adjusted life-year (QALY) as the effectiveness measure.…”

Comparing the Incomparable? A Systematic Review of Competing Techniques for Converting Descriptive Measures of Health Status into QALY-Weights

“…A number of TTU derivation studies report regression-based mappings from disease-specific descriptive measures to generic utility-based measures for osteoarthritis, 16 obesity, 29 schizophrenia, 30 hydrocephalus, 31 stable angina, 32 coronary artery disease, 33 and asthma. 34 For example, Melsop and others 33 predicted TTO scores from a battery of measures (R 2 = 0.31), including the Duke Activity Status Index (DASI), self-rated health status (text continued on p. 77) Bosch and Hunink 9 Brazier and Roberts 43 Brazier and others 29 Brazier and others 42 Brazier and others 41 Bult and others 10 Clayson and others 30 Daley and others 47 Donnelly and others 56 Franks and others 23 Franks and others 24 Fryback and others 6 Fryback and others 11 Gray and others 39 Haby and others 55 Heuzenroeder and others 53 Kind and Macran 48 Kulkarni 31 Lawrence and Fleishman 25 Lenert and others 45 Lenert and others 46 …”